Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPLOT: Repotrectinib With or Without Fulvestrant in HR+/HER2- Metastatic Invasive Lobular Carcinoma
NCT06408168Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of repotrectinib in Invasive Lobular Carcinoma (ILC), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2024; status: terminated.
02
Drugs
repotrectinib
03
Conditions
Invasive Lobular Carcinoma (ILC)
Beyond the preview
Go deeper on NCT06408168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06408168.